C=o In A C(=o)o Group (e.g., Nicotinic Acid, Etc.) Patents (Class 514/356)
-
Publication number: 20140050797Abstract: The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the active pharmaceutical ingredient comprises a weakly basic active pharmaceutical ingredient having a solubility of not more than 100 ?g/mL at pH 6.8.Type: ApplicationFiled: June 6, 2013Publication date: February 20, 2014Inventors: Gopi VENKATESH, Luigi BOLTRI, Italo COLOMBO, Jin-Wang LAI, Flavio FABIANI, Luigi MAPELLI
-
Patent number: 8652519Abstract: A pharmaceutical tablet containing olmesartan medoxomil and amlodipine besylate, which has improved dissolvability. Said composition contains (A) olmesartan medoxomil and (B) amlodipine besylate as active ingredients and (C) a calcium-containing additive. A method of improving the dissolution properties of a pharmaceutical composition containing olmesartan medoxomil and amlodipine besylate by using said composition is also provided.Type: GrantFiled: November 17, 2011Date of Patent: February 18, 2014Assignee: Daiichi Sankyo Company, LimitedInventors: Shuichi Yada, Hideki Yano, Tsuyoshi Nagaike, Misato Yokoi
-
Publication number: 20140044668Abstract: Methods and compositions for the effect of Cholesteryl ester transfer protein (CETP) polymorphisms on mRNA splicing, statin treatment outcome, response to CETP inhibitor drugs, and myocardial infarction risk are described.Type: ApplicationFiled: February 15, 2012Publication date: February 13, 2014Applicant: THE OHIO STATE UNIVERSITYInventors: Wolfgang Sadee, Audrey C. Papp
-
Publication number: 20140045801Abstract: The present invention relates to a method for the treatment and prevention of cluster headaches and migraines using the transdermal administration of pramipexole.Type: ApplicationFiled: August 9, 2012Publication date: February 13, 2014Applicant: MYLAN INC.Inventor: David Thomas Rossi
-
Publication number: 20140045904Abstract: Compositions and methods for reducing the flushing effect (cutaneous erythema) of niacin and for treating hyper lipemia and elevated triglycerides, comprising a prenylflavonoid, such as xanthohumol, and niacin (nicotinic acid or Vitamin B3).Type: ApplicationFiled: October 10, 2011Publication date: February 13, 2014Inventor: Eric Hauser Kuhrts
-
Publication number: 20140045874Abstract: The present invention is directed to compositions for preventing or reducing the flush and other unpleasant symptoms that sometimes accompany the consumption of alcoholic beverages, and methods for use of said compositions. The compositions comprise an agent, or combinations of various agents, such as an agent capable of increasing intracellular or intramitochondrial concentration of NAD in the subject; an agent capable of increasing glutathione concentration in the subject; an anti-oxidant; alpha-lipoic acid or a precursor to alpha-lipoic acid; and/or an agent capable of increasing the level of Coenzyme A in the subject; where the agent or agents are present or administered in amounts effective to prevent or reduce the alcohol reaction in a subject who has consumed one or more alcoholic beverages.Type: ApplicationFiled: July 9, 2013Publication date: February 13, 2014Applicant: NOGLO LLCInventors: Robert J. TOLLETH, Spencer A. GORDON
-
Publication number: 20140039017Abstract: This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.Type: ApplicationFiled: October 9, 2013Publication date: February 6, 2014Inventor: Robert Andrew Donald
-
Publication number: 20140037574Abstract: The invention provides a pharmaceutical composition for oral administration of a pharmaceutically active agent to a subject, including the pharmaceutically active agent and an inhibitor of CYP3A4. Administration of the inhibitor and the pharmaceutically active agent reduces pre-systemic degradation of the pharmaceutically active agent by CYP3A4. The inhibitor can be poly(ethylene glycol), methoxy poly(ethylene glycol), aminated poly(ethylene glycol), O-(2-aminoethyl)-O-methoxy poly(ethylene glycol), polyoxyethylene glycol, branched poly(ethylene glycol), 3-arm poly(ethylene glycol), 4-arm poly(ethylene glycol), 8-arm-poly(ethylene glycol)polyamine, poly(L-lysine), poly(L-arginine), poly(L-alanine), poly(L-valine), poly(L-serine), poly(L-histidine), poly(L-isoleucine), poly(L-leucine), poly(L-glutamic acid), poly(L-glutamine), poly(L-guanidine), poly(methyl methacrylate), polyvinyl acetate, polyacrylate, poly(lactic-co-glycolic acid) and derivatives thereof. A method of treatment is also described.Type: ApplicationFiled: November 28, 2011Publication date: February 6, 2014Inventors: Pius Sedowhe Fasinu, Viness Pillay, Yahya Essop Choonara, Lisa Claire Du Toit
-
Publication number: 20140030340Abstract: A method for preparing poorly water soluble drug particles is disclosed. The method comprises dissolving a drug in at least one organic solvent to form a drug/organic mixture, spraying the drug/organic mixture into an aqueous solution and concurrently evaporating the organic solvent in the presence of the aqueous solution to form an aqueous dispersion of the drug particles. The resulting drug particles are in the nanometer to micrometer size range and show enhanced dissolution rates and reduced crystallinity when compared to the unprocessed drug. The present invention additionally contemplates products and processes for new drug formulations of insoluble drug particles having high dissolution rates and extremely high drug-to-excipient ratios.Type: ApplicationFiled: October 3, 2013Publication date: January 30, 2014Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Keith P. Johnston, Robert O. Williams, III, Xiaoxia Chen
-
Patent number: 8637080Abstract: The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane.Type: GrantFiled: June 25, 2008Date of Patent: January 28, 2014Assignee: Osmotica Kereskedelmi és Szolgáltató, KFTInventors: Ana C. Pastini, Joaquina Faour, Juan A. Vergez, Marcelo A. Ricci, Gustavo A. Fischbein
-
Patent number: 8633229Abstract: The present invention relates to a pharmaceutical composition having dopaminergic activity and other related pharmaceutical activities comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s); a process of preparing a pharmaceutical composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s), wherein the process comprising steps of: (a) extracting a clear solution containing trigonelline and 4-hydroxyisoleucine from plant source; and (b) optionally precipitating derivative(s) of trigonelline and 4-hydroxyisoleucine from the clear solution and obtaining said composition; and an in-vitro method to increase levels of dopamine or to inhibit prolactin by allowing composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s) to bind to cell receptors.Type: GrantFiled: March 3, 2008Date of Patent: January 21, 2014Assignee: INDUS Biotech Pvt. Ltd.Inventors: Sunil Bhaskaran, Mohan Vishwaraman
-
Patent number: 8633192Abstract: Compositions and their use in the treatment or prevention of hyperglycemia and related diseases or disorders are disclosed.Type: GrantFiled: December 14, 2007Date of Patent: January 21, 2014Assignee: TIMA FoundationInventors: Markus Matuschka-Greiffenclau, Haruhiko Inufusa
-
Publication number: 20140017329Abstract: A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TR?1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TR?1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.Type: ApplicationFiled: July 10, 2013Publication date: January 16, 2014Inventor: Shaker A. Mousa
-
Publication number: 20140005233Abstract: A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.Type: ApplicationFiled: June 17, 2013Publication date: January 2, 2014Applicant: The Medicines CompanyInventors: Rajeshwar Motheram, Gopal Krishna, Min Ding, Keith Flood, Kornepati Ramakrishna
-
Patent number: 8618174Abstract: The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 19, 2011Date of Patent: December 31, 2013Assignee: Novartis AGInventors: William Hewitt, Daniel L Vasella, Randy L Webb
-
Publication number: 20130344116Abstract: The present invention relates to compositions and methods of the preparation of an oral particle essentially consisting of an amorphous structure and a submicron domain, wherein both amorphous structure and submicron domain comprise a drug, and wherein the particle shows crystalline property. The desired ratio of the amorphous structure to the submicron domain is between 0.1:5 and 1:1. And, the desired average particle diameter is between mesh 12 (1680 microns) and mesh 100 (149 microns).Type: ApplicationFiled: October 29, 2012Publication date: December 26, 2013Applicant: Magnifica Inc.Inventors: David Wong, James A. Lee, Peter P. Yang
-
Publication number: 20130344144Abstract: The invention relates to an extended-release matrix formulation capable of being directly compressed into tablets comprising niacin, a release-retarding agent, and other excipients. The resulting tablets of the invention demonstrate favorable release characteristics and a reduction in the severity, duration and incidences of cutaneous flushing commonly associated with niacin treatment.Type: ApplicationFiled: January 15, 2013Publication date: December 26, 2013Applicant: AbbVie Inc.Inventor: AbbVie Inc.
-
Publication number: 20130336902Abstract: A personal care composition is disclosed comprising a di-amido gellant, wherein the di-amido gellant has a formula: wherein R1 and R2 are aminofunctional end-groups which may be the same or different, and L is a linking moiety of molecular weight from 14 to 500 g/mol. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion and/or may comprise one or more actives or agents.Type: ApplicationFiled: June 13, 2012Publication date: December 19, 2013Inventors: SUSANA FERNANDEZ PRIETO, JOHAN SMETS, BEATRIU ESCUDER GIL, JUAN FELIPE MIRAVET CELADES, VICENT JOSEP NEBOT CARDA, PAUL ROBERT TANNER
-
Publication number: 20130338199Abstract: The present invention discloses (1) phenolic ester hybrids of niacin with m-methoxy-p-hydroxy phenyl compounds like eugenol, vanillin, apocynin, ferulic acid, isoferulic acid and eugenol epoxide and (2) cocrystals of hybrids as above, particularly cocrystal of niacin-eugenol hybrid with cocrystal former like eugenol and oxalic acid (3) novel pharmaceutical compositions comprising a combination of niacin and one or more small molecule/potentiating agent like eugenol, curcumin, cinnamic acid, meclofenamic acid, and their use in the treatment of a disorder or a disease caused by excess production of amyloid beta peptide-42 (A?42), its deposition, accumulation, and plaque formation including Alzheimer's Disease, dementia and mild cognitive impairment as well as other neurodegenerative diseases such as Parkinson's Disease, Huntington's disease, multiple sclerosis, amytrophic lateral sclerosis and ischemic stroke.Type: ApplicationFiled: August 20, 2013Publication date: December 19, 2013Inventors: Uday Saxena, Venkateswarlu Akella
-
Publication number: 20130337051Abstract: The present invention relates to the field of encapsulation of substances with low aqueous solubility in liposomes, especially via active loading. The present inventors have surprisingly found that efficient active loading of liposomes with high liposome loading can be achieved by first solubilizing a functional compound, which is itself hardly soluble in water using a solubility enhancer. This significantly increases the functional-substance-to-lipid mass ratio to levels above those attained by conventional active or passive loading techniques and enlarges the range of functional compounds, including drugs, amenable to encapsulation in liposomes. One aspect of the invention provides the active loading process. Liposomal compositions with high drug-load are provided by the present invention as well.Type: ApplicationFiled: March 1, 2012Publication date: December 19, 2013Inventors: Pieter Jaap Gaillard, Chantal Catharina Maria Appeldoorn, Jacob Rip
-
Patent number: 8604054Abstract: The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent. The triglyceride-lowering agent and hyperinsulinemia-ameliorating agent are characterized by containing a pitavastatin compound, and amlodipine or a salt thereof.Type: GrantFiled: December 22, 2011Date of Patent: December 10, 2013Assignees: Kowa Co., Ltd., Nissan Chemical Industries, Ltd.Inventors: Toru Yokoyama, Taro Aoki
-
Publication number: 20130324525Abstract: The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.Type: ApplicationFiled: August 6, 2013Publication date: December 5, 2013Applicant: Gilead Sciences, Inc.Inventors: Matthew Abelman, Robert H. Jiang, Jeff Zablocki
-
Publication number: 20130309302Abstract: The present invention relates to manufacturing processes for the preparation of a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil and optionally at least one diuretic characterized in that nifedipine is released in the body in a controlled (modified) manner and the candesartan cilexetil is released rapidly (immediate release (IR)) and optionally the diuretic is released rapidly (immediate release (IR)) and the pharmaceutical dosage forms obtainable by these processes.Type: ApplicationFiled: May 7, 2013Publication date: November 21, 2013Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventor: Bayer Pharma Aktiengesellschaft
-
Publication number: 20130303548Abstract: Niacin prevents and/or reverses the development of experimental hepatic steatosis, deposition of triglycerides in liver and serum of individuals, deposition of total cholesterol in liver and serum in individuals, and inhibit liver lipid peroxidation and oxidative stress in individuals at risk of developing fatty liver disease or NAFLD. In cultured human hepatocytes, niacin inhibits alcohol-induced fat accumulation.Type: ApplicationFiled: November 22, 2011Publication date: November 14, 2013Applicant: The Regents of the University of CaliforniaInventors: Moti L. Kashyap, Shobha V. Kamanna, Vaijinath S. Kamanna
-
Publication number: 20130302431Abstract: The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.Type: ApplicationFiled: March 13, 2013Publication date: November 14, 2013Inventors: R. Loch Macdonald, Cara R. Davis, Kevin Burton, Gary Winchester, Angela R. Stella
-
Patent number: 8574619Abstract: A method of reducing the cholesterol level of a subject by administering to that subject quercetin, vitamin C, vitamin B3, and statin.Type: GrantFiled: September 5, 2008Date of Patent: November 5, 2013Assignee: Quercegen Pharmaceuticals, LLCInventor: Thomas Christian Lines
-
Publication number: 20130289019Abstract: One embodiment of an aspect of the present invention is a method for lessening the symptoms of depression, anxiety, and post-traumatic stress disorder comprising the step of administering a therapeutically effective quantity of a cholinergic M1 receptor antagonist and a therapeutically effective quantity of one or more cholinomimetic agents to lessen the symptoms of depression, anxiety, and post-traumatic stress disorder. Typically, the cholinergic M1 receptor antagonist is selected from the group consisting of telenzepine, amytriptyline, biperiden, trihexyphenidyl, darifenacin, dicyclomine, and tiotropium. Another aspect of the present invention is directed to methods and compositions employing other therapeutic agents and combinations of therapeutic agents for emulating the theoretical pharmacological effects of the non-selective mAChR antagonist scopolamine. The invention also encompasses pharmaceutical compositions incorporating one or more therapeutic agents and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 25, 2013Publication date: October 31, 2013Applicant: Amazing Grace, Inc.Inventor: David T. Chau
-
Publication number: 20130280330Abstract: A nanosphere or microsphere drug carrier, formulations comprising the drug carrier and the preparation method of the formulations and the use of the carrier are disclosed. The carrier comprises a biodegradable methoxy end-capped polyethylene glycol-polylactide block copolymersor a derivative thereof represented by formula (I) as the main carrier material: CH3O—[CH2—CH2—O]m—[C(O)—CH(CH3)—O]n—R (I).Type: ApplicationFiled: July 30, 2010Publication date: October 24, 2013Applicant: XI'AN LIBANG MEDICAL TECHNOLOGY CO., LTD.Inventors: Renle Hu, Jiucheng Wang, Tao Chen, Hua Liang, Duohao Ding, Yaqi Jiao
-
Publication number: 20130273019Abstract: A method for treating a patient suffering from a wound, ulcer, or inflammation includes providing a topical formulation comprising a carrier and a combination of active ingredients that includes at least one retinoid and at least one blood vessel dilator, and applying the topical formulation to the skin of the patient to cause healing, accelerated healing or prevention of the wound, ulcer or inflammation. Additional active ingredients may include a promoter of mitochondrial function or an antioxidant.Type: ApplicationFiled: December 4, 2012Publication date: October 17, 2013Inventor: BioChemics, Inc.
-
Publication number: 20130274297Abstract: The invention provides a composite of drug, polymeric carrier and at least one not cross linked polymer useful to improve the solubility of poorly water soluble drugs. The present invention comprises manufacturing process of this composite material. The manufacturing process is carried out by the solvent induced activation process, wherein the not cross-linked polymer is loaded into the composite from organic solution, possibly together with the drug. Pharmaceutical compositions comprising said composite in combination with pharmaceutical acceptable excipients are also described herein.Type: ApplicationFiled: December 22, 2011Publication date: October 17, 2013Applicant: APTALIS PHARMA LIMITEDInventors: Paolo Gatti, Italo Colombo, Dario Gervasoni, Vincenza Pironti, Lia Alborghetti, Flavio Fabiani, Luigi Boltri
-
Patent number: 8557865Abstract: A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed.Type: GrantFiled: June 21, 2010Date of Patent: October 15, 2013Assignee: Calosyn Pharma, Inc.Inventor: David D. Waddell
-
Publication number: 20130251664Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.Type: ApplicationFiled: March 8, 2013Publication date: September 26, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: Richard T. Lee
-
Publication number: 20130252945Abstract: An amorphous formulations of a pharmaceutical includes a composition of the formula [A]x[MpClq]y, the composition being an ionic liquid with a melting temperature below 150° C., wherein [MpClq] is a metal chloride, x is 1, 2, 3, or 4, p is 1, 2, 3, or 4, q is 1, 2, 3, 4, 5, 6, 7, 8, or 9, and y is 1 or 2, wherein each A is a cation that is a pharmaceutical or a cation precursor that is a pharmaceutical.Type: ApplicationFiled: March 25, 2013Publication date: September 26, 2013Inventors: Katherine Lovejoy, Rico Del Sesto, Andrew Koppisch
-
Publication number: 20130243864Abstract: The described invention provides a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury using a flowable sustained release particulate composition.Type: ApplicationFiled: March 11, 2013Publication date: September 19, 2013Inventor: R. Loch Macdonald
-
Publication number: 20130216560Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.Type: ApplicationFiled: June 20, 2011Publication date: August 22, 2013Applicant: ZORA BIOSCIENCES OYInventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Minna Jänis, Riikka Katainen, Kirill Tarasov
-
Publication number: 20130217731Abstract: This document provides methods and materials relating to obesity. For example, methods and materials related to treating obesity and identifying agents having the ability to treat obesity are provided.Type: ApplicationFiled: March 27, 2013Publication date: August 22, 2013Applicant: Mayo Foundation for Medical Education and ResearchInventor: Mayo Foundation for Medical Education and Research
-
Publication number: 20130210867Abstract: Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction utilize L-arginine or equivalents and/or derivatives thereof, and an agent that enhances the activity of the L-arginine or equivalent thereof. These enhancing agents include niacin and/or nicotinamide. Niacin and/or nicotinamide, in combination with L-arginine or its equivalent allow a desired amount of nitric oxide to be delivered or generated at the female genitals in order to increase vasodilation and blood flow to the area to enhance sexual arousal and/or pleasure and to treat sexual dysfunction.Type: ApplicationFiled: April 15, 2011Publication date: August 15, 2013Applicant: LIFE SCIENCE ENHANCEMENT CORPORATIONInventors: Guy M. Stofman, Michael J. Pelekanos
-
Publication number: 20130209562Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.Type: ApplicationFiled: March 13, 2013Publication date: August 15, 2013Applicant: ALZA CORPORATIONInventor: ALZA CORPORATION
-
Publication number: 20130210758Abstract: A relaxation formulation structured to induce a deep state of relaxation in a person comprises amounts of tryptophan, melatonin, vitamin B3, and vitamin B6. Another relaxation formulation also includes an amount of tyrosine, and yet another formulation includes an amount of vitamin B12. At least one embodiment of a relaxation formula comprises a physiologically effective amount of gamma-aminobutyric acid (“GABA”). A delivery system is provided to facilitate administration of the relaxation formulation to a person. The delivery system may include an edible high carbohydrate matrix, such as a chocolate brownie. Alternatively, the delivery system may comprise an inert vaporizable compound to allow the components of the relaxation formulation to be inhaled directly into the lungs of a person. Other delivery systems include an aqueous sublingual spray and a beverage.Type: ApplicationFiled: May 4, 2012Publication date: August 15, 2013Inventor: Raymond M. Keller
-
Patent number: 8507548Abstract: This invention relates to a method of treating addiction using a composition containing quercetin. Preferably, it also contains vitamin B3, and vitamin C.Type: GrantFiled: August 23, 2011Date of Patent: August 13, 2013Assignee: Quercegen Pharmaceuticals LLCInventor: Thomas Christian Lines
-
Publication number: 20130203701Abstract: The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules. The invention further provides kits containing these pharmaceutical compositions, methods for formulating pharmaceutical compositions containing omega-3 oil, and methods for decreasing the likelihood of developing cardiovascular disease, decreasing triglyceride or LDL cholesterol levels, decreasing pain or inflammation, treating diabetes, chronic pulmonary diseases, or irritable bowel syndrome, decreasing symptoms of an autoimmune disease or allergic conditions.Type: ApplicationFiled: September 15, 2011Publication date: August 8, 2013Applicant: Maine Natural Health, Inc.Inventor: Harry J. Leighton
-
Publication number: 20130189342Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.Type: ApplicationFiled: March 16, 2011Publication date: July 25, 2013Applicant: TITAN PHARMACEUTICALS, INC.Inventors: Rajesh A. Patel, Sunil R. Bhonsle
-
Patent number: 8492413Abstract: New compounds of 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid ester type having general formula I wherein R is a lower alkyl group, which is methyl or ethyl R1 and R2 is sodium carboxylate-methyl ester, having synergistic cytotoxic effect combined with 5-fluorouracil.Type: GrantFiled: March 11, 2010Date of Patent: July 23, 2013Assignee: JSC GrindeksInventors: Gunars Duburs, Egils Bisenieks, Irina Sestakova, Ivars Kalvinsh, Brigita Vigante, Janis Uldrikis, Ilona Domraceva, Elina Jascenko, Janis Poikans, Imanta Bruvere, Ilmars Stonans
-
Publication number: 20130178464Abstract: Delta crystalline form of the compound of formula (I): characterised by its X-ray powder diffraction diagram. Medicinal products containing the same which are useful in the treatment of cardiovascular diseases.Type: ApplicationFiled: January 3, 2013Publication date: July 11, 2013Applicant: LES LABORATOIRES SERVIERInventor: LES LABORATOIRES SERVIER
-
Patent number: 8481570Abstract: The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin.Type: GrantFiled: June 11, 2012Date of Patent: July 9, 2013Assignee: Cortria CorporationInventors: Robert Bender, Stefan Chlopicki, Jerzy Gebicki
-
Publication number: 20130172392Abstract: A granule or a tablet of a solid dispersion that allows a drug in a preparation to be rapidly dissolved without impairing dissolving of the solid dispersion, and a method for producing same is composed of 1 to 10% by weight of a poorly soluble drug, a water-soluble polymer, an excipient and 15 to 50% by weight if a disintegrator; a tablet of a solid dispersion composed of a poorly soluble drug, 1 to 5% by weight of a water-soluble polymer, an excipient and 15 to 50% by weight of a disintegrator; and a method for producing a granule or tablet of a solid dispersion comprising spraying a water-soluble polymer solution, in which a poorly soluble drug has been dispersed or dissolved, on a mixed powder of an excipient and a disintegrator, and granulating and drying a resultant.Type: ApplicationFiled: December 11, 2012Publication date: July 4, 2013Applicant: SHIN-ETSU CHEMICAL CO., LTD.Inventor: SHIN-ETSU CHEMICAL CO., LTD.
-
Publication number: 20130171120Abstract: This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, epigallocatechin gallate, epicatechin, epicatechin gallate, and epigallocatechin.Type: ApplicationFiled: November 16, 2012Publication date: July 4, 2013Applicant: THE FRS COMPANYInventor: THE FRS COMPANY
-
Publication number: 20130156855Abstract: One example embodiment includes a chemical composition for the treatment of acne. The chemical composition includes pantothenic acid and L-Carnitine.Type: ApplicationFiled: December 16, 2011Publication date: June 20, 2013Inventor: Aviv Ben-Menachem
-
Publication number: 20130157986Abstract: Pharmaceutical compounds and compositions are provided which are methylenedioxy phenolic compounds and their derivatives, along with methods of making them and methods of using them for therapeutic purposes. The compounds and compositions are advantageous in that they can be used to treat or prevent cardiovascular disease, vascular disease and/or inflammatory disease, as well as Type I and Type II Diabetes and Dyslipidemia patients at risk for hypertension, stroke, cardiovascular and renal disease.Type: ApplicationFiled: June 12, 2012Publication date: June 20, 2013Applicants: INVASC THERAPEUTICS, INC., OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: SAMPATH PARTHASARATHY, SANJAY RAJAGOPALAN, DESIKAN RAJAGOPAL
-
Publication number: 20130158079Abstract: Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities.Type: ApplicationFiled: February 12, 2013Publication date: June 20, 2013Applicant: The Medicines CompanyInventor: The Medicines Company